Dexcom empowers people to take control of diabetes through innovative continuous glucose monitoring systems.
Founded in 1999, Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
The Dexcom G6 CGM is the first real-time, integrated continuous glucose monitoring system (iCGM) that is authorized to work interoperably with a range of connected insulin pen and hybrid closed-loop system partners. It features a 10-day sensor and requires zero fingersticks or scanning,* supporting greater freedom and flexibility for your patients ages two years and older to manage their diabetes.
Feature & Benefits
- Accuracy and Outcomes
Dexcom G6 features an overall MARD† of 9.0%.1 Dexcom CGM use is clinically proven to lower HbA1C, reduce hyper- and hypoglycemia, and increase time in range.2,3
- Real-Time Continuous Glucose Monitoring (RT-CGM) Real-time glucose readings are sent straight to your patient’s smart device§ or receiver as frequently as every five minutes.
- Remote Monitoring
Your patients can choose to share their glucose data with up to 10 followers.|| Should patients also give their followers the ability to receive alert notifications, followers can help patients stay in range.
- Indicated for Two Years and Older
Dexcom is the only provider of CGM systems indicated for children ages two years and older, and Dexcom G6 extends the benefits of remote monitoring to the same patient age range.§,||
- Urgent Low Soon Alert
Warn patients in advance of potentially dangerous low glucose values (55 mg/dL or below) and is associated with reduced hypoglycemia, without a corresponding increase in hyperglycemia.¶,4
* If your glucose alerts and readings from Dexcom G6 CGM System do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
§ Smart devices sold separately. To view a list of compatible smart devices, visit dexcom.com/compatibility.
† MARD is a statistical measure of accuracy.
|| Separate Dexcom Follow app required. Internet connectivity required for data sharing.
Followers should always confirm readings on the Dexcom G6 app or receiver before making treatment decisions. Followers must have compatible smart devices to use the Dexcom Follow app.
¶ This predictive alert can be triggered with impending hypoglycemia (glucose of 55 mg/
dL or below is predicted to occur within the next 20 minutes).
1 Shah VN, et al. Diabetes Technol Ther. 2018;20(6):428-433.
2 Beck, RW, et al. JAMA. 2017;317(4):371-378.
3 Welsh, JB et al. Diabetes Technol Ther. 2019;21(3): 128-132.
4 Puhr S, et al. Diabetes Technol Ther 2019;21(4):155-8.
This post is related to:Revenue Stream Opportunities